A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.

Exclusion Criteria

• •Subjects meeting any of the following criteria will be excluded from the study:
• •1. A skin examination reveals the presence of another skin disease and/or condition (excessive facial hair, excessive scarring, sunburn, or other disfigurement) located on the face that would confound the evaluation of the rosacea condition.
• •2. Current or past ocular rosacea, such as conjunctivitis, iritis, and keratitis, of sufficient severity to require topical or systemic antibiotics.
• •3. Treatment with topical antibiotics, topical steroids and other topical rosacea treatments on the face within 14 days of Baseline and throughout the study.
• •4. Treatment with systemic steroids within 30 days of Baseline and throughout the study.
• •5. Treatment with any systemic antibiotics within 30 days of Baseline and throughout the study.
• •6. Treatment with any systemic medication or therapy known to affect inflammatory responses within the 30 days prior to Baseline or throughout the study.
• •7. Treatment with topical retinoids within 30 days or systemic retinoids within 180 days of Baseline and throughout the study.
• •8. Treatment with physical modalities that could benefit rosacea are prohibited within 30 days of Baseline and throughout the study.